Armata Pharmaceuticals Stock News

MARINA DEL REY, Calif., Sept. 21, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics fo

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Armata Pharmaceuticals, Inc. (ARMP) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ARMP's 50-day simple moving average broke out ab

LOS ANGELES , Aug. 14, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeut

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.30 per share a year ago.

MARINA DEL REY, Calif. , Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophag

Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street a

MARINA DEL REY, Calif. , Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriopha

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 0% and 98.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -50% and 30.11%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the st

MARINA DEL REY, Calif. , March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacterioph

MARINA DEL REY, Calif., Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage

Armata Pharmaceuticals Inc (NYSE: ARMP ) has received $45 million of equity investment from its largest shareholder, Innoviva Inc (NASDAQ: INVA ), following a $4.0 million investment in Q4 of 2021. Armata will use the proceeds to advance its clinical pipeline and strengthen its bacteriophage platform. AP-PA02 leads the pipeline, currently under evaluation in the ''SWARM-P.a.'' trial for chronic Pseudomonas aeruginosa infections in people with cystic fibrosis. A second study, ''diSArm,'' is evaluating AP-SA02 in patients with complicated Staphylococcus aureus … Full story available on Benzinga.com

Armata Pharmaceuticals Inc. (ARMP) shares closed today 13.1% lower than it did at the end of yesterday. The stock is currently up 8.4% year-to-date, up 72.2% over the past 12 months, and up 23.1% over the past five years. Today, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Shares traded as high as $6.46 and as low as $5.30 this week.Shares closed 50.8% below its 52-week high and 83.0% above its 52-week low.Trading volume this week was 51.3% higher than the 10-day average and 4.5% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price lags the S&P 500 Index today, beats it on a 1-year basis, and lags it on a 5-year basis The company's share price lags the Dow Jones Industrial Average today, beats it on a 1-year basis, and lags it on a 5-year basis The company share price lags the performance of its peers in the Health Care industry sector today, beats it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -250.5% The company's stock price performance over the past 12 months beats the peer average by -237.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.